Citations (43)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (6)
Ronan Mahon, Jasper Huels, Victoria Hacking, Philip Cooney, Andriy Danyliv, Umakanth Vudumula, Sreelatha Vadapalle, Pamela Vo, Farooq H. Maniyar, Stephen Palmer & Peter J. Goadsby. (2020) Economic evaluations in migraine: systematic literature review and a novel approach. Journal of Medical Economics 23:8, pages 864-876.
Read now
Read now
Tinna Laufey Ásgeirsdóttir, Kristín Helga Birgisdóttir, Hanna Björg Henrysdóttir & Thorhildur Ólafsdóttir. (2020) Health-related quality of life and compensating income variation for 18 health conditions in Iceland. Applied Economics 52:15, pages 1656-1670.
Read now
Read now
Georgia Hollier-Hann, Alistair Curry, Kateryna Onishchenko, Ron Akehurst, Fayyaz Ahmed, Brendan Davies & Ian Keyzor. (2020) Updated cost-effectiveness analysis of onabotulinumtoxinA for the prevention of headache in adults with chronic migraine who have previously received three or more preventive treatments in the UK. Journal of Medical Economics 23:1, pages 113-123.
Read now
Read now
Richard B. Lipton, Alan Brennan, Stephen Palmer, Anthony J. Hatswell, Joshua K. Porter, Sandhya Sapra, Guillermo Villa, Neel Shah, Stewart Tepper & David Dodick. (2018) Estimating the clinical effectiveness and value-based price range of erenumab for the prevention of migraine in patients with prior treatment failures: a US societal perspective. Journal of Medical Economics 21:7, pages 666-675.
Read now
Read now
Rubesh Gooriah & Fayyaz Ahmed. (2015) OnabotulinumtoxinA for chronic migraine: a critical appraisal. Therapeutics and Clinical Risk Management 11, pages 1003-1013.
Read now
Read now
Francisco Javier Carod-Artal. (2014) Tackling chronic migraine: current perspectives. Journal of Pain Research 7, pages 185-194.
Read now
Read now
Articles from other publishers (37)
Hema Mistry, Seyran Naghdi, Martin Underwood, Callum Duncan, Jason Madan & Manjit Matharu. (2023) Competing treatments for migraine: a headache for decision-makers. The Journal of Headache and Pain 24:1.
Crossref
Crossref
Xinyu Wang, Kentaro Yamato, Yoshitsugu Kojima, Josef J. Paris, Elisabeth F. P. Peterse, Martijn J. H. G. Simons & Craig Bennison. (2023) Modeling Monthly Migraine-Day Distributions Using Longitudinal Regression Models and Linking Quality of Life to Inform Cost-Effectiveness Analysis: A Case Study of Fremanezumab in Japanese-Korean Migraine Patients. PharmacoEconomics.
Crossref
Crossref
Mustafa Karaoğlan. (2023) Three men in a boat: The comparison of the combination therapy of botulinum toxin and greater occipital nerve block with bupivacaine, with botulinum toxin monotherapy in the management of chronic migraine. Clinical Neurology and Neurosurgery 226, pages 107609.
Crossref
Crossref
Saval Khanal, Martin Underwood, Seyran Naghdi, Anna Brown, Callum Duncan, Manjit Matharu & Hema Mistry. (2022) A systematic review of economic evaluations of pharmacological treatments for adults with chronic migraine. The Journal of Headache and Pain 23:1.
Crossref
Crossref
Paolo Martelletti. 2022. Migraine in Medicine. Migraine in Medicine
1
209
.
Katja Kollewe, Charly Gaul, Astrid Gendolla & Katherine Sommer. (2021) Real-life use of onabotulinumtoxinA reduces healthcare resource utilization in individuals with chronic migraine: the REPOSE study. The Journal of Headache and Pain 22:1.
Crossref
Crossref
Igor Wilderman, Deborah Tallarigo & Olga Pugacheva-Zingerman. (2021) A Qualitative Study to Explore Patient Perspectives of Prophylactic Treatment with OnabotulinumtoxinA for Chronic Migraine. Pain and Therapy 10:2, pages 1523-1536.
Crossref
Crossref
Katja Kollewe, Charly Gaul, Astrid Gendolla & Katherine Sommer. (2021) Lebensqualität steigt, Inanspruchnahme von Gesundheitsleistungen sinkt. Schmerzmedizin 37:5, pages 50-55.
Crossref
Crossref
Ronan Mahon, Andrea Lang, Pamela Vo, Jasper Huels, Philip Cooney, Andriy Danyliv, Umakanth Vudumula, Sreelatha Vadapalle, Farooq Maniyar & Peter J. Goadsby. (2021) Cost-Effectiveness of Erenumab for the Preventive Treatment of Migraine in Patients with Prior Treatment Failures in Sweden. PharmacoEconomics 39:3, pages 357-372.
Crossref
Crossref
Sina J. Torabi, David A. Kasle, Emily L. Savoca, Christopher H. Gottschalk & R. Peter Manes. (2020) Characterizing the providers of and reimbursement for chronic migraine chemodenervation among the Medicare population. Headache: The Journal of Head and Face Pain 61:2, pages 373-384.
Crossref
Crossref
Amanda Hansson-Hedblom, Isabelle Axelsson, Lena Jacobson, Joakim Tedroff & Fredrik Borgström. (2020) Economic consequences of migraine in Sweden and implications for the cost-effectiveness of onabotulinumtoxinA (Botox) for chronic migraine in Sweden and Norway. The Journal of Headache and Pain 21:1.
Crossref
Crossref
Marta Torres-Ferrus, Victor José Gallardo, Alicia Alpuente & Patricia Pozo-Rosich. (2020) Influence of headache pain intensity and frequency on migraine-related disability in chronic migraine patients treated with OnabotulinumtoxinA. The Journal of Headache and Pain 21:1.
Crossref
Crossref
P. P. Cheang. (2020) Botulinum Toxin for Headache: a Comprehensive Review. Current Otorhinolaryngology Reports 8:4, pages 369-377.
Crossref
Crossref
Matteo Ruggeri, Carlo Drago, Francesco Rosiello, Valentina Orlando & Costanza Santori. (2020) Economic Evaluation of Treatments for Migraine: An Assessment of the Generalizability Following a Systematic Review. PharmacoEconomics 38:5, pages 473-484.
Crossref
Crossref
Gian Luca Di Tanna, Joshua K. Porter, Richard B. Lipton, Anthony J. Hatswell, Sandhya Sapra & Guillermo Villa. (2019) Longitudinal assessment of utilities in patients with migraine: an analysis of erenumab randomized controlled trials. Health and Quality of Life Outcomes 17:1.
Crossref
Crossref
Gian Luca Di Tanna, Joshua K. Porter, Richard B. Lipton, Alan Brennan, Stephen Palmer, Anthony J. Hatswell, Sandhya Sapra & Guillermo Villa. (2019) Migraine day frequency in migraine prevention: longitudinal modelling approaches. BMC Medical Research Methodology 19:1.
Crossref
Crossref
Emma McManus, David Turner & Tracey Sach. (2019) Can You Repeat That? Exploring the Definition of a Successful Model Replication in Health Economics. PharmacoEconomics 37:11, pages 1371-1381.
Crossref
Crossref
Theodoros V. Giannouchos, Dimos-Dimitrios Mitsikostas, Robert L. Ohsfeldt, Athanassios Vozikis & Paraskevi Koufopoulou. (2019) Cost-Effectiveness Analysis of Erenumab Versus OnabotulinumtoxinA for Patients with Chronic Migraine Attacks in Greece. Clinical Drug Investigation 39:10, pages 979-990.
Crossref
Crossref
Louis S. Matza, Kristen A. Deger, Pamela Vo, Farooq Maniyar & Peter J. Goadsby. (2019) Health state utilities associated with attributes of migraine preventive treatments based on patient and general population preferences. Quality of Life Research 28:9, pages 2359-2372.
Crossref
Crossref
Hanieh Mimeh, Anna Maria Fenech Magrin, Simon Myers & Ali M Ghanem. (2019) A Critical Review of Botulinum Toxin Type A in the Prophylactic Treatment of Chronic Migraine in Adults. Aesthetic Surgery Journal 39:8, pages 898-907.
Crossref
Crossref
A.B. Gago-Veiga, S. Santos-Lasaosa, M.L. Cuadrado, Á.L. Guerrero, P. Irimia, J.M. Láinez, R. Leira, J. Pascual, M. Sanchez del Río, J. Viguera & P. Pozo-Rosich. (2019) Evidence and experience with onabotulinumtoxinA in chronic migraine: Recommendations for daily clinical practice. Neurología (English Edition) 34:6, pages 408-417.
Crossref
Crossref
A.B. Gago-Veiga, S. Santos-Lasaosa, M.L. Cuadrado, Á.L. Guerrero, P. Irimia, J.M. Láinez, R. Leira, J. Pascual, M. Sanchez del Río, J. Viguera & P. Pozo-Rosich. (2019) Evidencia y experiencia de bótox en migraña crónica: Recomendaciones para la práctica clínica diaria. Neurología 34:6, pages 408-417.
Crossref
Crossref
Lars Bendtsen, Simona Sacco, Messoud Ashina, Dimos Mitsikostas, Fayyaz Ahmed, Patricia Pozo-Rosich & Paolo Martelletti. (2018) Guideline on the use of onabotulinumtoxinA in chronic migraine: a consensus statement from the European Headache Federation. The Journal of Headache and Pain 19:1.
Crossref
Crossref
A. Castrillo Sanz, N. Morollón Sánchez-Mateos, C. Simonet Hernández, B. Fernández Rodríguez, D. Cerdán Santacruz, A. Mendoza Rodríguez, M.F. Rodríguez Sanz, C. Tabernero García, P. Guerrero Becerra, M. Ferrero Ros & J. Duate García-Luis. (2018) Experience with botulinum toxin in chronic migraine. Neurología (English Edition) 33:8, pages 499-504.
Crossref
Crossref
Matthew Sussman, Jennifer Benner, Peter Neumann & Joseph Menzin. (2018) Cost-effectiveness analysis of erenumab for the preventive treatment of episodic and chronic migraine: Results from the US societal and payer perspectives. Cephalalgia 38:10, pages 1644-1657.
Crossref
Crossref
Clare P Herd, Claire L Tomlinson, Caroline Rick, W J Scotton, Julie Edwards, Natalie Ives, Carl E Clarke & Alexandra Sinclair. (2018) Botulinum toxins for the prevention of migraine in adults. Cochrane Database of Systematic Reviews 2018:6.
Crossref
Crossref
Larry CharlestonIVIV, Jeffrey Royce, Teshamae S. Monteith, Susan W. Broner, Hope L. O'Brien, Salvador L. Manrriquez & Matthew S. Robbins. (2018) Migraine Care Challenges and Strategies in US Uninsured and Underinsured Adults: A Narrative Review, Part 2. Headache: The Journal of Head and Face Pain 58:5, pages 633-647.
Crossref
Crossref
James E. Frampton & Stephen Silberstein. (2018) OnabotulinumtoxinA: A Review in the Prevention of Chronic Migraine. Drugs 78:5, pages 589-600.
Crossref
Crossref
Cristina Tassorelli, Marco Aguggia, Marina De Tommaso, Pierangelo Geppetti, Licia Grazzi, Luigi Alberto Pini, Paola Sarchielli, Gioacchino Tedeschi, Paolo Martelletti & Pietro Cortelli. (2017) Onabotulinumtoxin A for the management of chronic migraine in current clinical practice: results of a survey of sixty-three Italian headache centers. The Journal of Headache and Pain 18:1.
Crossref
Crossref
Inigo Bermejo, Paul Tappenden & Ji-Hee Youn. (2017) Replicating Health Economic Models: Firm Foundations or a House of Cards?. PharmacoEconomics 35:11, pages 1113-1121.
Crossref
Crossref
A. Castrillo Sanz, N. Morollón Sánchez-Mateos, C. Simonet Hernández, B. Fernández Rodríguez, D. Cerdán Santacruz, A. Mendoza Rodríguez, M.F. Rodríguez Sanz, C. Tabernero García, P. Guerrero Becerra, M. Ferrero Ros & J. Duate García-Luis. (2016) Experiencia con toxina botulínica en la migraña crónica. Neurología.
Crossref
Crossref
Richard L. Barbano. (2016) Botulinum toxins in clinical practice. Neurology Clinical Practice 6:3, pages 206-208.
Crossref
Crossref
María Isabel Pedraza, Carolina de la Cruz, Marina Ruiz, Luis López-Mesonero, Elena Martínez, Mercedes de Lera & Ángel Luis Guerrero. (2015) OnabotulinumtoxinA treatment for chronic migraine: experience in 52 patients treated with the PREEMPT paradigm. SpringerPlus 4:1.
Crossref
Crossref
Délia Szok, Anett Csáti, László Vécsei & János Tajti. (2015) Treatment of Chronic Migraine with OnabotulinumtoxinA: Mode of Action, Efficacy and Safety. Toxins 7:7, pages 2659-2673.
Crossref
Crossref
Carlos Federico Buonanotte. (2015) Costo beneficio del tratamiento de la migra?a cr?nica con Onabotulinumtoxin A en Argentina. Neurolog?a Argentina 7:2, pages 84-88.
Crossref
Crossref
Robert G. Kaniecki, Frederick R. Taylor & Stephen H. Landy. (2014) Abstracts and Citations. Headache: The Journal of Head and Face Pain 54:4, pages 757-765.
Crossref
Crossref
Michel Lanteri-Minet. (2013) Economic Burden and Costs of Chronic Migraine. Current Pain and Headache Reports 18:1.
Crossref
Crossref